X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Aardvark will acquire certain assets and intellectual property of the Company that pertain to ADAIR, a proprietary abuse-deterrent formulation of immediate release dextroamphetamine, for the development of certain follow-on pipeline programs.
Lead Product(s): Amphetamine
Therapeutic Area: Psychiatry/Psychology Product Name: ADAIR
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: GRI Bio
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Agreement August 23, 2023
Details:
ARD-101, is a first-in-class oral composition that has shown promising activity in reducing hunger cravings in clinical studies and promoting weight loss in pre-clinical studies and which is investigated for the treatment of prader-willi yndrome.
Lead Product(s): Denatonium Acetate
Therapeutic Area: Genetic Disease Product Name: ARD-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
Details:
ARD-101 (denatonium acetate) is a first-in-class oral substantially gut-restricted with minimal systemic exposure yet conveys systemic effects via activation of GLP-1, GLP-2, and which show positive impact on hunger scores in general obesity and Prader-Willi Syndrome.
Lead Product(s): Denatonium Acetate
Therapeutic Area: Genetic Disease Product Name: ARD-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of California
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
ARD-301 is comprised of a non-opioid, non-addictive therapy option that has been shown to have activity for improving a broad array of fibromyalgia symptoms in prior clinical studies with LDN.
Lead Product(s): Naltrexone
Therapeutic Area: Musculoskeletal Product Name: ARD-301
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sorrento Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
